| 30 July 2024 | ||||
| | | | | |
| IMI plc ("IMI" or the "Company") | ||||
| | ||||
| Transaction in Own Shares | ||||
| | | | | |
| LEI: 2138002W9Q21PF751R30 | ||||
| | | | | |
| IMI announces that on 30 July 2024 it purchased through Merrill Lynch International the following number of its ordinary shares for cancellation at an average price of 1,856.7370 pence per share: | ||||
| | | | | |
| Date of purchase: | 30 July 2024 | |||
| Number of ordinary shares purchased: | 67,143 | |||
| Highest purchase price paid per share: | 1,867.00p | |||
| Lowest purchase price paid per share: | 1,849.00p | |||
| Volume weighted average price paid per share: | 1,856.74p | |||
| | | | | |
| Following the above transaction, the Company has 274,985,909 ordinary shares in issue and holds 13,648,836 ordinary shares in treasury. Therefore the total number of voting rights in the Company is 261,337,073 which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IMI plc under the FCA's Disclosure Guidance and Transparency Rules. | ||||
| | | | | |
| Aggregated Information | ||||
|
| | | | |
| Date | Trading venue | Volume weighted average price (£ per share) | Number of Shares Purchased | |
| 30 July 2024 | London Stock Exchange | 18.56 | 46,300 | |
| 30 July 2024 | Chi-X (CXE) | 18.59 | 9,605 | |
| 30 July 2024 | BATS (BXE) | 18.58 | 8,168 | |
| 30 July 2024 | Turquoise | 18.59 | 3,070 | |
| | | | | |
| Transaction Details |
| | | |
| | | | | |
| In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014 as it forms part of UK law, a full breakdown of the individual trades made by Merrill Lynch International on behalf of the Company as part of the Programme is detailed on the attached: | ||||
| | | | | |
| http://www.rns-pdf.londonstockexchange.com/rns/4688Y_1-2024-7-30.pdf | ||||
| | | | | |
| Enquiries: | | | | |
| | | | | |
| IMI plc | | | | |
| Louise Waldek, Company Secretary | ||||
| 0121 717 3700 | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.